Andera Partners Co-Leads €105 Million Series A for Adcytherix

Andera Partners has announced its co-lead of a €105 million Series A funding round for Adcytherix, marking the first investment from its BioDiscovery 7 fund. This financing was jointly led by Angelini Ventures, Bpifrance, and Kurma Partners. The investment aims to progress Adcytherix's lead program, ADCX-020, into clinical trials, with investigational new drug (IND) and clinical trial applications (CTA) expected by the end of 2025.

Adcytherix, a biopharmaceutical firm based in Marseille, focuses on novel antibody drug conjugates (ADCs) for cancer treatment. Its approach includes leveraging unique payloads for targeted therapies. The funding will also support the company's efforts to expand its ADC pipeline.

Sofia Ioannidou from Andera Partners expressed optimism about this investment, highlighting Adcytherix's expertise and strategic focus. The financing underscores collaborative support and shared objectives among the involved investors to advance innovative cancer treatments.